Hyperglycemia Treatment Market Research Report- Global Forecast till 2023

Hyperglycemia Treatment Market Research Report- Global Forecast till 2023

ID: MRFR/HC/3146-HCRR | April, 2018 | Region: Global | 95 pages | Half-Cooked Research Reports

Hyperglycemia Treatment Market Information: By Treatment (Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Drugs), Mode of Administration (Topical, Oral), End User (Hospitals & Clinics, Retail Pharmacy) - Global Forecast till 2023 


Market Scenario


Hyperglycemia is an excess of glucose in the bloodstream, and is often associated with diabetes mellitus. It occurs when the body does not have enough insulin to control the sugar level or unable to produce the insulin. Furthermore, hyperglycemia if remains untreated may cause serious complications such as nerve damage or neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease, and skin problems such as bacterial and fungal infections. The major signs of hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate often), and a dry mouth.


Increasing prevalence of diabetes, and growing investment in biotechnology and pharmaceutical industries, and rising need for the better treatment methods drive the growth of the market.


According to the WHO, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes. Another, 2.2 million deaths were attributed to high blood glucose level in 2012.


According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies across the globe. This is higher than the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.


Moreover, increasing awareness about diabetes care and management, and advancing technology in medical devices are adding fuel to the growth of the market. Furthermore, increasing prevalence of obesity and consumption of unhealthy diet also drive the market growth. 


However, availability of expensive treatment and poor reimbursement policy are some of the factors, which may slow the market growth during the forecast period.


The global hyperglycemia treatment market is expected to grow at a CAGR of  9.8 % during the forecast period 2017-2023.


 


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities



Figure: Global Hyperglycemia Treatment Market, By Region Market Share, 2016 (%)

Hyperglycemia Treatment Market


               Sources: Annual reports, Press release, White paper, Company presentation


 


Segmentations


The global hyperglycemia treatment market is segmented on the basis of treatment, mode of administration, and end user.


On the basis of treatment, it is segmented into fluid replacement, electrolyte replacement, insulin therapy, and drugs. The drugs segment is further segmented into sulfonylureas, biguanides, thiazolidinediones, and others.


On the basis of mode of administration, it is segmented into topical, oral, and others.


On the basis of end user, the market is segmented into hospitals & clinics, retail pharmacy, and others


Regional Analysis


The Americas dominates the global hyperglycemia treatment market owing to well-developed technology, increasing patient with diabetes, increasing prevalence of neurological disorders, increasing patient population of kidney failure caused by severe hyperglycemia, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the global hyperglycemia treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.


Asia Pacific is the fastest growing hyperglycemia treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as  the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the hyperglycemia treatment in the region.


On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.


Key Players


Some of key the players in the market are Novo Nordisk A/S, Merck & Company Inc., Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd., Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb., and Abbott.


 


Research Methodology

Hyperglycemia Treatment Market-


Sources: Annual reports, Press release, White paper, and Company presentation







TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hyperglycemia treatment Market, by Treatments

6.1 Introduction

6.2 Fluid Replacement

6.2.1 Market Estimates & Forecast, 2017 – 2023

6.3 Electrolyte Replacement

6.3.1 Market Estimates & Forecast, 2017 – 2023

6.4 Insulin Therapy

6.4.1 Market Estimates & Forecast, 2017 – 2023

6.5 Drugs

6.5.1 Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Hyperglycemia Treatment Market, by Mode of administration

7.1 Introduction

7.2 Topical

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Oral

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Others

7.4.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Hyperglycemia Treatment Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Retail Pharmacy

8.3.2 Market Estimates & Forecast, 2017 – 2023

8.4 Others

Chapter 9. Global Hyperglycemia Treatment Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Novo Nordisk AS

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Medtronic Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Merck & Company Inc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Teva Pharmaceuticals Pvt Ltd

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Eli Lilly and Company

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Bristol-Myers Squibb

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Bayer AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Hyperglycemia Treatment industry

Chapter 13 Appendix





LIST OF TABLES

Table 1 Hyperglycemia Treatment Industry Synopsis, 2017 – 2023

Table 2 Global Hyperglycemia treatment Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Hyperglycemia Treatment Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Hyperglycemia treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 5 Global Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 6 Global Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 8 North America Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 9 North America Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 11 US Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 12 US Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 14 Canada Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 15 Canada Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 17 South America Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 18 South America Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 20 Europe Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 21 Europe Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 23 Western Europe Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 24 Western Europe Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Hyperglycemia Treatment Market by Treatment, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Hyperglycemia Treatment Market by Mode of Administration, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Hyperglycemia Treatment Market by End Users, 2017 – 2023, (USD Million)





LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hyperglycemia Treatment Market

Figure 3 Segmentation Market Dynamics for Global Hyperglycemia Treatment Market

Figure 4 Global Hyperglycemia Treatment Market Share, by Product 2016

Figure 5 Global Hyperglycemia Treatment Market Share, by Application 2016

Figure 6 Global Hyperglycemia treatment Market Share, by End Users, 2016

Figure 7 Global Hyperglycemia Treatment Market Share, by Region, 2016

Figure 8 North America Hyperglycemia Treatment Market Share, by Country, 2016

Figure 9 Europe Hyperglycemia Treatment Market Share, by Country, 2016

Figure 10 Asia Pacific Hyperglycemia Treatment Market Share, by Country, 2016

Figure 11 Middle East & Africa Hyperglycemia Treatment Market Share, by Country, 2016

Figure 12 Global Hyperglycemia Treatment Market: Company Share Analysis, 2016 (%)

Figure 13 Novo Nordisk AS: Key Financials

Figure 14 Novo Nordisk AS: Segmental Revenue

Figure 15 Novo Nordisk AS: Geographical Revenue

Figure 16 Medtronic Inc.: Key Financials

Figure 17 Medtronic Inc.: Segmental Revenue

Figure 18 Medtronic Inc.: Geographical Revenue

Figure 19 Merck & Company Inc.: Key Financials

Figure 20 Merck & Company Inc.: Segmental Revenue

Figure 21 Merck & Company Inc.: Geographical Revenue

Figure 22 Teva Pharmaceuticals Pvt Ltd: Key Financials

Figure 23 Teva Pharmaceuticals Pvt Ltd: Segmental Revenue

Figure 24 Teva Pharmaceuticals Pvt Ltd: Geographical Revenue

Figure 25 Eli Lilly and Company: Key Financials

Figure 26 Eli Lilly and Company: Segmental Revenue

Figure 27 Eli Lilly and Company: Geographical Revenue

Figure 28 Bristol-Myers Squibb: Key Financials

Figure 29 Bristol-Myers Squibb: Segmental Revenue

Figure 30 Bristol-Myers Squibb: Geographical Revenue

Figure 31 Bayer AG: Key Financials

Figure 32 Bayer AG: Segmental Revenue

Figure 33 Bayer AG: Geographical Revenue